These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 22155238

  • 1. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
    Merabet N, Bellien J, Glevarec E, Nicol L, Lucas D, Remy-Jouet I, Bounoure F, Dreano Y, Wecker D, Thuillez C, Mulder P.
    J Mol Cell Cardiol; 2012 Mar; 52(3):660-6. PubMed ID: 22155238
    [Abstract] [Full Text] [Related]

  • 2. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.
    Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F, Henry JP, Mulder P, Thuillez C.
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):260-7. PubMed ID: 22075752
    [Abstract] [Full Text] [Related]

  • 3. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C.
    Circulation; 2004 Apr 06; 109(13):1674-9. PubMed ID: 14981003
    [Abstract] [Full Text] [Related]

  • 4. Reduced cardiac remodelling and prevention of glutathione deficiency after omega-3 supplementation in chronic heart failure.
    Fang Y, Favre J, Vercauteren M, Laillet B, Remy-Jouet I, Skiba M, Lallemand F, Dehaudt C, Monteil C, Thuillez C, Mulder P.
    Fundam Clin Pharmacol; 2011 Jun 06; 25(3):323-32. PubMed ID: 20584202
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.
    Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C.
    Eur Heart J; 2008 Sep 06; 29(17):2171-9. PubMed ID: 18586661
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H.
    J Am Coll Cardiol; 2004 Oct 19; 44(8):1679-89. PubMed ID: 15489104
    [Abstract] [Full Text] [Related]

  • 11. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
    Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S.
    J Pharmacol Exp Ther; 2003 Apr 19; 305(1):97-105. PubMed ID: 12649357
    [Abstract] [Full Text] [Related]

  • 12. Antibody to granulocyte macrophage colony-stimulating factor reduces the number of activated tissue macrophages and improves left ventricular function after myocardial infarction in a rat coronary artery ligation model.
    Kellar RS, Lancaster JJ, Thai HM, Juneman E, Johnson NM, Byrne HG, Stansifer M, Arsanjani R, Baer M, Bebbington C, Flashner M, Yarranton G, Goldman S.
    J Cardiovasc Pharmacol; 2011 May 19; 57(5):568-74. PubMed ID: 21326109
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J.
    Basic Res Cardiol; 2014 Jul 19; 109(4):421. PubMed ID: 24907870
    [Abstract] [Full Text] [Related]

  • 16. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
    Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM.
    Am J Physiol Heart Circ Physiol; 2008 Nov 19; 295(5):H2128-34. PubMed ID: 18835921
    [Abstract] [Full Text] [Related]

  • 17. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.
    Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K.
    Am J Physiol Heart Circ Physiol; 2008 Jun 19; 294(6):H2838-44. PubMed ID: 18441205
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients.
    Tran L, Kompa AR, Wang BH, Krum H.
    Cardiovasc Ther; 2012 Oct 19; 30(5):295-300. PubMed ID: 21884016
    [Abstract] [Full Text] [Related]

  • 19. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
    Roche C, Besnier M, Cassel R, Harouki N, Coquerel D, Guerrot D, Nicol L, Loizon E, Remy-Jouet I, Morisseau C, Mulder P, Ouvrard-Pascaud A, Madec AM, Richard V, Bellien J.
    Am J Physiol Heart Circ Physiol; 2015 May 01; 308(9):H1020-9. PubMed ID: 25724490
    [Abstract] [Full Text] [Related]

  • 20. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
    Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J.
    Circulation; 2008 Aug 19; 118(8):818-27. PubMed ID: 18678774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.